US Patent Issued to Takeda Pharmaceutical on May 20 for "Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer" (Massachusetts Inventor)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,303,724, issued on May 20, was assigned to Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer" was invented by Adedigbo Fasanmade (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides, inter alia, methods of treating a disorder characterized by pathological activity of CD30+ cells, such as in certain solid, hematological and lymphoid cancers, in a non-adult human subject by administering an effective amount of an anti-CD30 ADC (antibody drug conjugate), such as, brentuximab vedotin, to the subject. The invention a...